Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Drug Metabolism And Disposition

• Publication date

  2003-07-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1124/DMD.31.7.945PMID 12814973
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• In vitro forecasting of drugs which may interfere with the biotransformation of midazolam

  2004cited by this paper
• A pharmacokinetic interaction between roxithromycin and midazolam

  2004influential reference
• The pharmacokinetics of midazolam in man

  2004cited by this paper
• Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data.

  2001cited by this paper
• Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin.

  2001cited by this paper
• Prediction of In Vivo Interaction Between Triazolam and Erythromycin Based on In Vitro Studies Using Human Liver Microsomes and Recombinant Human CYP3A4

  2000cited by this paper
• An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation.

  2000cited by this paper
• Prediction of in vivo drug-drug interactions based on mechanism-based inhibition from in vitro data: inhibition of 5-fluorouracil metabolism by (E)-5-(2-Bromovinyl)uracil.

  2000influential reference
• The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin

  1998cited by this paper
• In vitro and in vivo drug interactions involving human CYP3A.

  1998cited by this paper
• Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver.

  1998cited by this paper
• Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin.

  1998cited by this paper
• Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data.

  1997cited by this paper
• Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism.

  1997cited by this paper
• Oral first‐pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A‐mediated metabolism

  1996cited by this paper
• Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam.

  1996influential reference
• [Protein binding of clarithromycin in patients with chronic renal failure].

  1996cited by this paper
• Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole.

  1996cited by this paper
• Interaction between midazolam and clarithromycin: comparison with azithromycin.

  1996influential reference
• The erythromycin breath test predicts the clearance of midazolam

  1995cited by this paper
• Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily.

  1994cited by this paper
• Inhibition of Human CYP3A Catalyzed 1′-Hydroxy Midazolam Formation by Ketoconazole, Nifedipine, Erythromycin, Cimetidine, and Nizatidine

  1994cited by this paper
• Comparison of the Effect of the Macrolide Antibiotics Erythromycin, Clarithromycin and Azithromycin on Terfenadine Steady-State Pharmacokinetics and Electrocardiographic Parameters

  1994cited by this paper
• Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals.

  1994cited by this paper
• A potent inhibitory effect of erythromycin and other macrolide antibiotics on the mono-N-dealkylation metabolism of disopyramide with human liver microsomes.

  1993cited by this paper
• A potentially hazardous interaction between erythromycin and midazolam.

  1993cited by this paper
• Pharmacokinetic Drug Interactions of Macrolides

  1992influential reference
• Pharmacokinetics of clarithromycin, a new macrolide, after single ascending oral doses

  1992influential reference
• Goodman and Gilman's The Pharmacological Basis of Therapeutics

  1991cited by this paper
• The pharmacokinetics of azithromycin in human serum and tissues.

  1990cited by this paper
• Single Oral Dose Pharmacokinetics of Erythromycin and Roxithromycin and the Effects of Chronic Dosing

  1990cited by this paper
• Induction of β-lactamase and methicillin resistance in unusual strains of methicillin-resistant Staphylococcus aureus

  1990cited by this paper
• Effects of clarithromycin on cytochrome P-450. Comparison with other macrolides.

  1989cited by this paper
• TE-031の体内動態 (第8報)

  1988cited by this paper
• Mechanism-based enzyme inactivation : chemistry and enzymology

  1988influential reference
• Mechanisms of the inhibition of cytochrome P-450-mediated drug oxidation by therapeutic agents.

  1987cited by this paper
• Goodman and Gilman's the Pharmacological Basis of Therapeutics

  1986cited by this paper
• Kinetics of suicide substrates. Practical procedures for determining parameters.

  1985cited by this paper
• Turnover of membrane proteins: kinetics of induction and degradation of seven forms of rat liver microsomal cytochrome P-450, NADPH-cytochrome P-450 reductase, and epoxide hydrolase.

  1984influential reference
• A pharmacokinetic analysis program (multi) for microcomputer.

  1981cited by this paper
• Kinetics of suicide substrates.

  1980cited by this paper
• Absorption following oral administration of erythromycin.

  1953cited by this paper
• Absorption following oral administration of erythromycin.

  1953cited by this paper

• Construction of physiologically based pharmacokinetic model to predict CYP1A autoinduction by multi-kinase inhibitor TSU-68 based on in vitro induction kinetics.

  2025cites this paper
• Understanding Voriconazole Metabolism: A Middle-Out Physiologically-Based Pharmacokinetic Modelling Framework Integrating In Vitro and Clinical Insights

  2024cites this paper
• Prioritization of Eleven-Nineteen-Leukemia Inhibitors as Orally Available Drug Candidates for Acute Myeloid Leukemia

  2024cites this paper
• Characterization of Pediatric Rectal Absorption, Drug Disposition, and Sedation Level for Midazolam Gel Using Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling.

  2024cites this paper
• Physiologically Based Pharmacokinetic Modeling to Assess the Drug-Drug Interactions of Anaprazole with Clarithromycin and Amoxicillin in patients undergoing eradication therapy of H. pylori infection.

  2023cites this paper
• Hyperkalemia by eplerenone or esaxerenone in the presence or absence of clarithromycin in hypertensive patients: a retrospective observational cohort study

  2023cites this paper
• [Drug interactions in neurosurgical patients].

  2023cites this paper
• The Prioritization of Eleven-Nineteen-Leukemia Inhibitors as Potential Drug Candidates to Treat Acute Myeloid Leukemia

  2022cites this paper
• Mechanism-based inhibition of CYP3A subfamilies by macrolide antibiotics and piperine.

  2022cites this paper
• Prediction of herb-drug interactions involving consumption of furanocoumarin-mixtures and cytochrome P450 1A2-mediated caffeine metabolism inhibition in humans.

  2021cites this paper
• Drug Interactions between Antimicrobial and Immunosuppressive Agents in Solid Organ Transplant Recipients

  2021cites this paper
• Application of population, physiologically based, and semi-physiological pharmacokinetic modeling to assess sources of pharmacokinetic variability in individual drugs

  2020influential citation
• A Novel Study Design Using Continuous Intravenous and Intraduodenal Infusions of Midazolam and Voriconazole for Mechanistic Quantitative Assessment of Hepatic and Intestinal CYP3A Inhibition.

  2020cites this paper
• The clinical significance of statins-macrolides interaction: comprehensive review of in vivo

  2019cites this paper
• The clinical significance of statins-macrolides interaction: comprehensive review of in vivo studies, case reports, and population studies

  2019cites this paper
• Pharmacokinetics Modeling and Molecular Modeling of Drug-Drug Interactions Between Opioids and Benzodiazepines

  2019cites this paper
• TCRM_A_214938 921..936

  2019cites this paper
• Improved predictions of time-dependent drug-drug interactions by determination of cytosolic drug concentrations

  2019cites this paper
• Interaction Potential between Clarithromycin and Individual Statins - a Systematic Review.

  2019cites this paper
• Characterization of Intestinal and Hepatic CYP3A-Mediated Metabolism of Midazolam in Children Using a Physiological Population Pharmacokinetic Modelling Approach

  2018cites this paper
• PBPK Models for CYP3A4 and P‐gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin

  2018cites this paper
• First‐Pass CYP3A‐Mediated Metabolism of Midazolam in the Gut Wall and Liver in Preterm Neonates

  2018cites this paper
• Translational physiologically-based pharmacokinetic (PBPK) modeling and simulation to support drug development and pharmacotherapy

  2018cites this paper
• Inactivation kinetics and residual activity of CYP3A4 after treatment with erythromycin

  2017cites this paper
• A quantitative systems pharmacology approach, incorporating a novel liver model, for predicting pharmacokinetic drug-drug interactions

  2017cites this paper
• A Perspective on the Kinetics of Covalent and Irreversible Inhibition

  2017cites this paper
• Is the current treatment of urogental and anorectal chlamydia infection appropriate

  2017cites this paper
• Inhibition of Caffeine Metabolism in Humans by Furanocoumarin-Containing Plant Extracts: In Vivo and In Vitro Studies

  2016cites this paper
• Evaluation of a New Molecular Entity as a Victim of Metabolic Drug-Drug Interactions—an Industry Perspective

  2016influential citation
• Clarithromycin, Midazolam, and Digoxin: Application of PBPK Modeling to Gain New Insights into Drug–Drug Interactions and Co-medication Regimens

  2016cites this paper
• Clinical Drug-Drug Interaction Data: Effects of Co-administered Drugs on Pharmacokinetics of Antiretroviral Agents

  2016cites this paper
• Clinically Significant Interactions with Anesthetic Agents

  2016cites this paper
• Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4

  2015cites this paper
• Concepts and applications for evidence-based dosing in morbidly obese patients before and after weight loss surgery

  2015cites this paper
• Cytochrome P450 time-dependent inhibition and induction: advances in assays, risk analysis and modelling

  2015cites this paper
• Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies.

  2015cites this paper
• Semiphysiologically based pharmacokinetic model for midazolam and CYP3A mediated metabolite 1‐OH‐midazolam in morbidly obese and weight loss surgery patients

  2015cites this paper
• PBPK Modeling and In Silico Prediction for ADME and Drug–Drug Interaction

  2015cites this paper
• The effects of CYP3A4 induction and inhibition on the pharmacokinetics of alisporivir in humans

  2015cites this paper
• Exploring concepts of in vitro time-dependent CYP inhibition assays

  2014cites this paper
• Management and Mitigation of Human Drug-drug Interaction Risks in the Drug Discovery and Development Phases

  2014cites this paper
• Rationalizing underprediction of drug clearance from enzyme and transporter kinetic data: from in vitro tools to mechanistic modeling.

  2014cites this paper
• Reduced Physiologically-Based Pharmacokinetic Model of Repaglinide: Impact of OATP1B1 and CYP2C8 Genotype and Source of In Vitro Data on the Prediction of Drug-Drug Interaction Risk

  2014cites this paper
• PBPK models for the prediction of in vivo performance of oral dosage forms.

  2014cites this paper
• Liver injury associated with ketoconazole: Review of the published evidence

  2014cites this paper
• Analysis of the repaglinide concentration increase produced by gemfibrozil and itraconazole based on the inhibition of the hepatic uptake transporter and metabolic enzymes (292.2)

  2014cites this paper
• Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin

  2013cites this paper
• A semi-physiologically-based pharmacokinetic model characterizing mechanism-based auto-inhibition to predict stereoselective pharmacokinetics of verapamil and its metabolite norverapamil in human.

  2013influential citation
• Analysis of the Repaglinide Concentration Increase Produced by Gemfibrozil and Itraconazole Based on the Inhibition of the Hepatic Uptake Transporter and Metabolic Enzymes

  2013cites this paper
• Prolonged sedation following administration of oral midazolam

  2013cites this paper
• A Semiphysiological Population Pharmacokinetic Model for Dynamic Inhibition of Liver and Gut Wall Cytochrome P450 3A by Voriconazole

  2013cites this paper
• Dynamic Modeling of Cytochrome P450 Inhibition In Vitro: Impact of Inhibitor Depletion on IC50 Shift

  2013cites this paper
• Camphor poisoning: Personal experience

  2013cites this paper
• Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME

  2013cites this paper
• Author’s Reply to Kotlinska-Lemieszek: “Should Midazolam Drug–Drug Interactions Be of Concern to Palliative Care Physicians?”

  2013cites this paper
• DMD049460 362..371

  2013cites this paper
• Evaluation of Drug–Drug Interaction Risk with PBPK Models

  2012cites this paper
• Progress Curve Mechanistic Modeling Approach for Assessing Time-Dependent Inhibition of CYP3A4

  2012cites this paper
• Predictive methods and strategy for drug-drug interactions caused by mechanism-based inhibition of drug metabolizing enzymes

  2012influential citation
• Tachycardia-induced cardiomyopathy presenting with cardiogenic shock.

  2012cites this paper
• A PBPK Model to Predict Disposition of CYP3A-Metabolized Drugs in Pregnant Women: Verification and Discerning the Site of CYP3A Induction

  2012cites this paper
• Pharmacological Actions of Statins: A Critical Appraisal in the Management of Cancer

  2012cites this paper
• Predictive methods and strategy for drug-drug interactions caused by mechanism-based inhibition of drug metabolizing enzymes

  2012cites this paper
• In vitro screening of reversible and time-dependent inhibition on CYP3A by TM208 and TM209 in rat liver microsomes

  2012cites this paper
• In Vitro Liver Systems to Study Induction/Inhibition: Prediction of In Vivo Metabolism and Drug–Drug Interactions

  2012cites this paper
• In Silico Models of Drug Metabolism and Drug Interactions

  2012cites this paper
• Extrahepatic Drug-Metabolizing Enzymes and Their Significance

  2012cites this paper
• Quantitative Prediction of Mechanism-Based Inhibition Caused by Mibefradil in Rats

  2011influential citation
• CYP3A Time-Dependent Inhibition Risk Assessment Validated with 400 Reference Drugs

  2011influential citation
• Assessment of cytochrome p450 enzyme inhibition and inactivation in drug discovery and development.

  2011cites this paper
• Prediction of drug-drug interactions arising from mechanism-based inactivation: key input parameters and impact on risk assessment.

  2011cites this paper
• Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models.

  2011cites this paper
• Microsoft Word-22828359-file00.docx

  2011cites this paper
• Prolonged sedation related to erythromycin and midazolam interaction: a word of caution.

  2011cites this paper
• KUCERS ' THE USE OF ANTIBIOTICS A CLINICAL REVIEW OF ANTIBACTERIAL , ANTIFUNGAL , ANTIPARASITIC AND ANTIVIRAL DRUGS VO , LUME

  2011cites this paper
• Drug interaction leading to prolonged sedation in a postoperative high risk coronary bypass surgery patient

  2011cites this paper
• Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover.

  2011cites this paper
• Uptake transporters of the human OATP family: molecular characteristics, substrates, their role in drug-drug interactions, and functional consequences of polymorphisms.

  2011cites this paper
• Determination of Time-Dependent Inactivation of CYP3A4 in Cryopreserved Human Hepatocytes and Assessment of Human Drug-Drug Interactions

  2011cites this paper
• Mechanism-based inhibition of CYP2C8 by gemfibrozil in humans : characterisation of time and dose relationships

  2011cites this paper
• Mechanism‐Based Inactivation of CYP2C8 by Gemfibrozil Occurs Rapidly in Humans

  2011cites this paper
• Modulation of pharmacokinetics of theophylline by antofloxacin, a novel 8-amino-fluoroquinolone, in humans

  2011cites this paper
• Evaluation of the Effects of Mitragyna speciosa Alkaloid Extract on Cytochrome P450 Enzymes Using a High Throughput Assay

  2011cites this paper
• CYP3A TIME DEPENDENT INHIBITION RISK ASSESSMENT VALIDATED WITH 400 REFERENCE DRUGS

  2011cites this paper
• Integrated in silico-in vitro strategy for addressing cytochrome P450 3A4 time-dependent inhibition.

  2010cites this paper
• Studies of the Toxicological Potential of Capsinoids, XIII: Inhibitory Effects of Capsaicin and Capsinoids on Cytochrome P450 3A4 in Human Liver Microsomes

  2010cites this paper
• The use of HepaRG and human hepatocyte data in predicting CYP induction drug-drug interactions via static equation and dynamic mechanistic modelling approaches.

  2010cites this paper
• Inhibition of CYP3A by Erythromycin: In Vitro-In Vivo Correlation in Rats

  2010cites this paper
• In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A

  2010cites this paper
• Use of clearance concepts and modeling techniques in the prediction of metabolic drug-drug interactions.

  2010cites this paper
• IC50-based approaches as an alternative method for assessment of time-dependent inhibition of CYP3A4

  2010cites this paper
• Metabolic bioactivation and drug-related adverse effects: current status and future directions from a pharmaceutical research perspective

  2010influential citation
• Consideration of reliable concentrations for prediction of change in enzyme activity by mechanism-based inactivation using physiologically-based pharmacokinetic model simulations.

  2010cites this paper
• Physiologically Based Pharmacokinetic Model of Mechanism-Based Inhibition of CYP3A by Clarithromycin

  2010influential citation
• Erythromycin as a prokinetic agent: risk factors.

  2010cites this paper
• Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects

  2010influential citation
• Species differences in mechanism-based inactivation of CYP3A in humans, rats and mice.

  2010cites this paper
• Prediction of pharmacokinetic drug-drug interaction caused by changes in cytochrome P450 activity using in vivo information.

  2010cites this paper
• Facteurs de risque de l’utilisation de l’érythromycine comme agent prokinétique

  2010cites this paper
• Clinical Studies of Drug–Drug Interactions: Design and Interpretation

  2010cites this paper